Sophia Genetics announced that its platform, Sophia DDM™, now hosts the world’s largest clinical genomics community for molecular diagnosis, placing Europe ahead of the US in precision medicine. Witnessing a 400% growth rate this year alone, it now supports over 100 institutions across 18 countries, rising to become the largest network globally for interpreting pseudonymised genomics data and sharing knowledge on genomic variants clinical interpretation.
All 100 plus institutions within the community use Sophia Genetics’ cutting edge analytical solution and its advanced machine learning algorithms to analyse the genetic make-up of some common cancers and inherited conditions, such as such as cystic fibrosis, so that clinicians can more accurately diagnose patients at speed and at scale.
Speaking about this key milestone moment, Jurgi Camblong, CEO and co-founder of Sophia Genetics commented: “Over the past 18 months, Sophia Genetics’ technology has been able to make precision medicine a reality for healthcare institutions across Europe, helping patients benefit from faster and more accurate diagnosis. I am thrilled that Sophia Genetics today has been recognised as the global leader in this field, and is helping Europe lead the wider healthcare industry in delivering the value and promises associated with personalised medicine.”
The company performed over 20,000 patient analyses in 2015, and expects to quadruple this number in 2016. Users of Sophia DDM™ include Oxford University Hospitals, Hospices Civils de Lyon, Val d’Hebron Hospital and University Hospital Cologne, which leverage Sophia Genetics’ industry-leading genetic analysis technology to provide clinicians the most accurate, fast and cost-effective means to offer genomic analysis of samples to their patients…
Source: Sophia Genetics